Pfizer Q2 FY26 swings to net loss of USD 248 million; revenue rises 3% to USD 15 billion
PFE•Guidance lifted for 2026
Pfizer raised its 2026 revenue guidance midpoint by USD 0.5 billion to USD 60.5 billion–USD 62.5 billion, citing stronger non-COVID products.
It reaffirmed 2026 adjusted diluted EPS (non-GAAP) at USD 2.8–USD 3, absorbing an expected USD 0.10 hit tied to the Innovent transaction.
Albert Bourla said launched and acquired products performed well, with momentum in obesity programs and oncology remaining a source of strength.
Q2 revenue rises, but reported results swing to a loss
Pfizer posted Q2 2026 revenue of USD 15 billion, up 3% year over year, with reported diluted EPS turning to a loss of USD 0.04.
Adjusted diluted EPS (non-GAAP) slipped to USD 0.77 from USD 0.78, while reported results reflected USD 4.3 billion of non-cash intangible asset impairments.
